アメリカのバイオ医薬品サードパーティロジスティクス市場規模は、予測期間中のCAGR 7.1%で2028年までに623億米ドルに達する見込みです。新規の生物製剤の需要が増加し、それらを管理する必要性が市場の成長を後押ししています。さらに、様々な地域で生物製剤を輸送するための温度管理された物流サービスの需要が高まっていることや、バイオ医薬品企業が販売を向上させるために流通ネットワークを拡大していることも、市場成長の要因となっています。
COVID-19のパンデミックは、航空貨物輸送能力の低下や、倉庫や空港での作業員の減少などにより、世界の物流にある程度大きな影響を与えました。また、ウイルスの感染を抑制するために、物流インフラを閉鎖したり、移動制限を行ったり、追加要件を設けたりする現地当局の決定も、物流サービスに影響を与えました。これにより、多くの供給活動が大きく妨げられました。
輸送や屋内退避に関する政府の規制が緩和されたことで、この市場は将来的に有利になると考えられています。パンデミックの際には、コールドチェーン・ロジスティクスの需要が急増しました。COVID-19ワクチンの製造・販売の成長は、2021年を通して期待されています。例えば、2021年3月、FedEx Express社は、McKesson Corp.社のCOVID-19ワクチンを全米のセンターに出荷し始めました。同社は2020年12月中旬以降、すでに数百万本のCOVID-19ワクチンを出荷しています。
目次
Table of Contents
Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Supply Chain
1.1.2 Services Type
1.1.3 Product Type
1.1.4 Regional Scope
1.1.5 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective - 1:
1.10.2 Objective - 2:
1.10.3 Objective - 3:
1.10.4 Objective - 4:
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Market Definition
3.1 By Supply Chain
3.2 By Services Type
3.3 By Product type
Chapter 4 U.S. Biopharmaceutical Third-Party Logistics Market: Variables, Trends, & Scope
4.1 Market Segmentation and Scope
4.2 Market Driver Analysis
4.2.1 Technological advancements in logistics
4.2.2 Growing applications of reverse logistics in biopharmaceutical industry
4.2.3 Rising demand for cold chain logistics
4.3 Market Restraint Analysis
4.3.1 Compliance Issues While Outsourcing
4.4 Penetration & Growth Prospect Mapping
4.5 Porter’s Five Forces Analysis
4.6 PESTEL Analysis
Chapter 5 Qualitative Information for Hub Services, Copay, and Adherence
5.1 Hub Services
5.2 Copay
5.3 Adherence
Chapter 6 U.S. Biopharmaceutical Third-Party Logistics Market: Supply Chain Segment Analysis
6.1 U.S. Biopharmaceutical Third-Party Logistics Market: Market Share Analysis, 2020 & 2028
6.2 Cold Chain Logistics
6.2.1 Cold Chain Logistics market, 2016 - 2028 (USD Billion)
6.3 Non-cold Chain Logistics
6.3.1 Non-cold Chain Logistics market, 2016 - 2028 (USD Billion)
Chapter 7 U.S. Biopharmaceutical Third-Party Logistics Market: Services Type Segment Analysis
7.1 U.S. Biopharmaceutical Third-Party Logistics Market: Market Share Analysis, 2020 & 2028
7.2 Transportation
7.2.1 Transportation market, 2016 - 2028 (USD Billion)
7.2.2 Air Freight
7.2.2.1 Air freight market, 2016 - 2028 (USD Billion)
7.2.3 Sea Freight
7.2.3.1 Sea freight market, 2016 - 2028 (USD Billion)
7.2.4 Overland Transportation
7.2.4.1 Overland transportation market, 2016 - 2028 (USD Billion)
7.3 Warehousing and Storage
7.3.1 Warehousing and Storage market, 2016 - 2028 (USD Billion)
7.4 Other Services
7.4.1 Other Services market, 2016 - 2028 (USD Billion)
Chapter 8 U.S. Biopharmaceutical Third-Party Logistics Market: Product Type Segment Analysis
8.1 U.S. Biopharmaceutical Third-Party Logistics Market: Market Share Analysis, 2020 & 2028
8.2 Specialty Drugs
8.2.1 Specialty Drugs market, 2016 - 2028 (USD Billion)
8.3 Generics
8.3.1 Generics market, 2016 - 2028 (USD Billion)
8.4 Plasma Derived Products
8.4.1 Plasma Derived Products market, 2016 - 2028 (USD Billion)
8.5 Others
8.5.1 Others market, 2016 - 2028 (USD Billion)
Chapter 9 Company Profiles
9.1 Company Profiles
9.1.1 FedEx
9.1.1.1 Company overview
9.1.1.2 Financial performance
9.1.1.3 Product benchmarking
9.1.2 DHL International GmbH
9.1.2.1 Company overview
9.1.2.2 Financial performance
9.1.2.3 Product benchmarking
9.1.3 SF Express
9.1.3.1 Company overview
9.1.3.2 Financial performance
9.1.3.3 Product benchmarking
9.1.4 United Parcel Service of America, Inc.
9.1.4.1 Company overview
9.1.4.2 Financial performance
9.1.4.3 Product benchmarking
9.1.4.4 Strategic initiatives
9.1.5 AmerisourceBergen Corporation
9.1.5.1 Company overview
9.1.5.2 Financial performance
9.1.5.3 Product benchmarking
9.1.6 DB Schenker
9.1.6.1 Company overview
9.1.6.2 Financial performance
9.1.6.3 Product benchmarking
9.1.7 KUEHNE + NAGEL
9.1.7.1 Company overview
9.1.7.2 Financial performance
9.1.7.3 Product benchmarking
9.1.8 Kerry Logistics Network Limited
9.1.8.1 Company overview
9.1.8.2 Financial performance
9.1.8.3 Product benchmarking
9.1.9 Agility
9.1.9.1 Company overview
9.1.9.2 Financial performance
9.1.9.3 Product benchmarking
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.S. Biopharmaceutical Third Party Logistics Market, By Supply Chain, 2016 - 2028 (USD Billion)
Table 4 U.S. Biopharmaceutical Third Party Logistics Market, By Service Type, 2016 - 2028 (USD Billion)
Table 5 U.S. Biopharmaceutical Third Party Logistics Market, By Transportation, 2016 - 2028 (USD Billion)
Table 6 U.S. Biopharmaceutical Third Party Logistics Market, By Product Type, 2016 - 2028 (USD Billion)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity Flow Analysis
Fig. 9 Volume Price Analysis
Fig. 10 U.S. biopharmaceutical third- party logistics market snapshot (2020)
Fig. 11 U.S. biopharmaceutical third- party logistics market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Reasons for non-adherence in the U.S.
Fig. 18 U.S. biopharmaceutical third-party logistics market supply chain outlook: Segment dashboard
Fig. 19 U.S. biopharmaceutical third-party logistics market: Supply chain movement analysis
Fig. 20 Cold chain logistics market, 2016 - 2028 (USD Billion)
Fig. 21 Non-cold chain logistics market, 2016 - 2028 (USD Billion)
Fig. 22 U.S. biopharmaceutical third-party logistics market services type outlook: Segment dashboard
Fig. 23 U.S. biopharmaceutical third- party logistics market: Services Type movement analysis
Fig. 24 Transportation market, 2016 - 2028 (USD Billion)
Fig. 25 Air freight market, 2016 - 2028 (USD Billion)
Fig. 26 Sea freight market, 2016 - 2028 (USD Billion)
Fig. 27 Overland transportation market, 2016 - 2028 (USD Billion)
Fig. 28 Warehousing and storage market, 2016 - 2028 (USD Billion)
Fig. 29 Other services market, 2016 - 2028 (USD Billion)
Fig. 30 U.S. biopharmaceutical third-party logistics market product type outlook: Segment dashboard
Fig. 31 U.S. Biopharmaceutical third-party logistics market: Product type movement analysis
Fig. 32 Specialty drugs market, 2016 - 2028 (USD Billion)
Fig. 33 Generics market, 2016 - 2028 (USD Billion)
Fig. 34 Plasma derived products market, 2016 - 2028 (USD Billion)
Fig. 35 Others market, 2016 - 2028 (USD Billion)
